logo
Plus   Neg
Share
Email

Genentech's Late-stage Study On Aggressive Leukemia Meets Primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said that the late-stage VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate.

The study showed Venclexta plus azacitidine helped people with the most common type of aggressive leukemia in adults live longer compared to azacitidine alone.

Safety for Venclexta plus azacitidine appeared consistent with the known safety profile of these medicines.

Venclexta is being developed by AbbVie and Genentech. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Many retailers including Target, Walmart and CVS announced temporary store closures in various regions across the United States following violence and looting amid the unrest related to the death of George Floyd. The street protests, some peaceful and some violent, erupted across the nation after Floyd was mercilessly killed by Minnesota police. Nestle USA, a division of Swiss food major Nestlé, announced the recall of certain Lean Cuisine Fettuccini Alfredo products citing misbranding and the presence of an undeclared allergen. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, the recall involves approximately 29,002 pounds of chicken products. Apple chief executive officer Tim Cook condemned the killing of an unarmed black man, George Floyd, and called for the creation of a "better, more just world for everyone," according to reports citing a memo to employees.
Follow RTT